MarginsXMarginsX
Home › Markets › Health Care › BSEM

BioStem Technologies Inc. (BSEM)

BSEM trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.9601
-8.56% on the day
Market cap
$18.4M
Nano cap
Revenue · 2025
$47.5M
-31.8% on 2024
Net income · 2025
-$6.6M
-13.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerBSEM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001658678
SEC industry codeBiological Products, (No Diagnostic Substances)
Incorporated inFL

Financials · 2025

LineValue
Revenue$47.5M
Net income-$6.6M
Operating income-$689K
Net margin-13.9%
Operating margin-1.5%
Revenue growth-31.8%
Cash$29.5M
Total assets$50.0M
P/E (computed)Net income was not positive
P/S (computed)0.4×

Warning signs

Cash runway
0.5 months
$971K cash at September 30, 2026
Share count, 1 year
No year-earlier count
Going-concern doubt
Yes
10-Q filed November 12, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Accordingly, substantial doubt exists about the Company's ability to continue as a going concern for at least one year from the issuance of these financial statements."
10-Q 2026-11-12
Cash and burn$971K cash; operating cash flow -$5.6M a quarter.Report 2026-09-30
Shares outstanding19,178,631 (2026-11-11).Cover page 2026-11-11
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Charlotte, North Carolina, United StatesPCAOB Form AP 2026-08-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$7.6M-$11.4M-$8.8M$971K$0Needs four quarters10-Q 2026-11-12
Q2 2026
2026-06-30
$7.9M-$9.0MNot filed$7.0M$0Needs four quarters10-Q 2026-08-12
Q3 2026
2025-09-30
$10.5M$761K-$2.4M$27.2MNo debt tagsNeeds four quarters10-Q 2026-11-12
Q2 2026
2025-06-30
$11.0M$11KNot filed$30.8MNo debt tagsNeeds four quarters10-Q 2026-08-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document
PROSPECTUS
424B32026-10-13
Latest quarterly / interim10-Q2026-11-12
Latest current report8-K2026-11-12

Source: SEC EDGAR submissions feed, 81 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-7.1%
1 month-53.3%
3 months-66.1%
Year to date-72.4%
1 year-74.6%
From 52-week high-87.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Biological Products (No Diagnostic Substances)

TickerCompanyPriceDayMarket cap
ESLAEstrella Immunopharma Inc.$0.3800-26.07%$16.5M
ABOSAcumen Pharmaceuticals Inc.$0.2160+0.93%$15.6M
PLURPluri Inc.$1.04-0.95%$15.0M
ATYRaTyr Pharma Inc.$5.24-14.17%$13.4M
PASGPassage Bio Inc.$4.13-2.82%$13.3M
EVAXEvaxion A/S American Depositary Share$2.77+0.54%$25.5M
MGXMetagenomi Therapeutics Inc.$0.6800-1.69%$25.7M
JSPRJasper Therapeutics Inc.$11.77-13.96%$13.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier